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Background: Amblyopia is a common neurodevelopmental disorder of vision that is characterised by visual
impairment in one eye and compromised binocular visual function. Existing evidence-based treatments for children
include patching the nonamblyopic eye to encourage use of the amblyopic eye. Currently there are no widely
accepted treatments available for adults with amblyopia. The aim of this trial is to assess the efficacy of a new
binocular, videogame-based treatment for amblyopia in older children and adults. We hypothesise that binocular
treatment will significantly improve amblyopic eye visual acuity relative to placebo treatment.
Methods/design: The BRAVO study is a double-blind, randomised, placebo-controlled multicentre trial to assess
the effectiveness of a novel videogame-based binocular treatment for amblyopia. One hundred and eight
participants aged 7 years or older with anisometropic and/or strabismic amblyopia (defined as ≥0.2 LogMAR
interocular visual acuity difference, ≥0.3 LogMAR amblyopic eye visual acuity and no ocular disease) will be
recruited via ophthalmologists, optometrists, clinical record searches and public advertisements at five sites in
New Zealand, Canada, Hong Kong and Australia. Eligible participants will be randomised by computer in a 1:1
ratio, with stratification by age group: 7–12, 13–17 and 18 years and older. Participants will be randomised to
receive 6 weeks of active or placebo home-based binocular treatment. Treatment will be in the form of a modified
interactive falling-blocks game, implemented on a 5th generation iPod touch device viewed through red/green
anaglyphic glasses. Participants and those assessing outcomes will be blinded to group assignment. The primary
outcome is the change in best-corrected distance visual acuity in the amblyopic eye from baseline to 6 weeks post
randomisation. Secondary outcomes include distance and near visual acuity, stereopsis, interocular suppression,
angle of strabismus (where applicable) measured at baseline, 3, 6, 12 and 24 weeks post randomisation.
Treatment compliance and acceptability will also be assessed along with quality of life for adult participants.
Discussion: The BRAVO study is the first randomised controlled trial of a home-based videogame treatment for
older children and adults with amblyopia. The results will indicate whether a binocular approach to amblyopia
treatment conducted at home is effective for patients aged 7 years or older.
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Trial registration: This trial was registered in Australia and New Zealand Clinical Trials Registry
(ACTRN12613001004752) on 10 September 2013.
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Amblyopia is a neurodevelopmental disorder of the vis-
ual system that is caused by abnormal binocular visual
experience during early childhood, typically due to an-
isometropia or strabismus [1]. Amblyopia causes a range
of monocular deficits in the affected eye including im-
paired visual acuity [1], contrast sensitivity [2], motion
perception [3, 4] and excessive crowding [5] (see [6] for
a recent review). Patients with amblyopia also experience
impaired binocular vision. In particular, the fellow eye
often suppresses the amblyopic eye when both eyes are
open, and stereopsis is commonly impaired or absent
[7]. Stronger interocular suppression has been associated
with poorer stereopsis and monocular visual acuity in
patients [8–11], as well as poorer amblyopic eye contrast
sensitivity in animal models of amblyopia [12, 13].
In children, the visual acuity deficit associated with
amblyopia can be treated monocularly by optically cor-
recting any significant refractive error and then occluding
(patching) or penalising (with atropine cycloplegia) the
fellow eye to encourage use of the amblyopic eye [14].
While effective, these monocular treatments may result
in adverse psychosocial effects [15–17] and compliance
can be low [18]. In addition, patching and atropine have
relatively high relapse rates after cessation of treatment
[19, 20], and they do not directly address binocular deficits
that are associated with amblyopia [21]. Therefore, re-
sidual monocular and binocular visual impairments often
remain after patching and/or atropine therapy [22].
Treatment of teenagers and adults with amblyopia is
also problematic. Conventional treatment can be effective
in teenagers [22] and a large number of laboratory-based
studies have reported that visual function can be improved
in adults with amblyopia using techniques such as monocu-
lar perceptual learning (reviewed by [23]). However, despite
this evidence, teenagers and adults with amblyopia are typ-
ically left untreated in mainstream clinical practice. This
may be because older patients are assumed to be unable to
improve, are not able to tolerate conventional treatments,
or because clinical trials have not assessed the treatment of
amblyopia in adults. There is a clear need for clinicians to
be provided with alternative treatment options for patients
of all ages that are supported by high-quality clinical trial
data [24–26].
In recent years a new binocular amblyopia treatment
approach has emerged [27] that is designed to reduce
suppression and strengthen binocular visual function[26, 28]. Binocular treatment is based on evidence that
patients with amblyopia have the ability to combine in-
formation between their eyes if suppression is minimised
by presenting stimuli at high contrast to the amblyopic
eye and at low contrast to the fellow eye (contrast balan-
cing) [29, 30]. This indicates that patients with amblyopia
may have a structurally intact, but functionally suppressed,
binocular visual system. Binocular treatment involves
tasks that require binocular combination of stimuli that
are presented dichoptically with a contrast offset in favour
of the amblyopic eye. As treatment progresses, the intero-
cular contrast difference is gradually reduced to promote
binocular fusion.
The first contrast balanced binocular treatment studies
involved repeated performance of a psychophysical motion
discrimination task under dichoptic presentation conditions
[27, 31]. Subsequent studies employed a falling-blocks
videogame that requires blocks moving down the screen
to be tessellated together [32]. The videogame can be
played using a pair of video goggles that allow for separate
images to be presented to each eye [33, 34] or on a tablet
computer device with images split between the two eyes
using a lenticular overlay screen or red/green anaglyphic
glasses [32, 35, 36]. Neither eye sees all of the game ele-
ments and, therefore, binocular combination is required
for successful game play.
There have been several case-series studies investigating
the effect of contrast balanced binocular treatment in
adults and children with amblyopia and the results are
promising [27, 31, 32, 34, 35, 37–42]. A recent review of
these studies reported an average improvement in ambly-
opic eye visual acuity of 0.24 logarithm of the minimum
angle of resolution (LogMAR) for adults (n = 84) and 0.16
LogMAR in compliant children (n = 91); significant im-
provements in stereopsis were also observed in both
adults and compliant children [26]. More recently, binocu-
lar treatment has been reported to improve fine motor
skills in a case-series of children with amblyopia [43]. Fur-
thermore, viewing of dichoptic, contrast balanced movies
was found to improve amblyopic eye visual acuity by 0.2
LogMAR in a group of children [44]. As a whole, the re-
sults from preliminary studies suggest that (1) contrast
balanced binocular treatment improves monocular and
binocular visual function in children and adults, (2) the
treatment is rapid, working within a matter of weeks and
(3) the effects last in excess of 1 month after the cessation
of treatment. The momentum behind these initial studies
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mised clinical trial of the treatment [45, 46], which we
hope to answer with this study.
A number of other binocular amblyopia treatment
approaches are in development (e.g. [47, 48]). Some are
also based on the use of contrast balancing, such as a
modified dichoptic first-person shooter videogame com-
bined with a monocular perceptual learning task [49].
Others, such as the I-BiT system [50, 51], involve dichop-
tic presentation of images without contrast balancing. The
I-BiT system involves the dichoptic presentation of videos
or videogames with the background presented to both
eyes and foreground elements presented only to the am-
blyopic eye. The treatment is targeted at children and aims
to improve amblyopic eye visual acuity.
A 2015 Cochrane Review reported no published ran-
domised controlled trials of any binocular intervention
in children with unilateral amblyopia aged 3–8 years
[52]. Subsequently, a randomised controlled trial (RCT)
evaluating of the effectiveness of the I-BiT system was
completed [53]. The trial compared the effect of 3 h
(30 min per week) of dichoptic videos versus dichoptic
videogames versus nondichoptic (control) videogames on
amblyopic eye visual acuity in children aged 4–8 years.
Amblyopic eye visual acuity improved by approximately
0.07 LogMAR in all three arms [53].
In addition, a RCT of contrast balanced binocular
treatment was recently completed [54]. This trial used
an adventure videogame called Dig Rush rather than the
falling-blocks game described above. Children of 4–10
years of age completed 10 h of binocular treatment (1 h
per day, 5 days per week) and 28 h of patching (2 h per
day, 7 days per week) following a randomised crossover
design. Contrast balanced binocular treatment resulted
in a significantly greater amblyopic eye visual acuity im-
provement than patching (0.15 LogMAR versus 0.07
LogMAR prior to crossover). A large-scale RCT compar-
ing contrast balanced binocular treatment delivered using
the falling-blocks game to patching (NCT02200211) will
also be complete in the near future.
Aside from the studies described above, a literature
search completed on 25 September 2016 using the same
search strategy employed within the 2015 Cochrane Re-
view by Tailor et al. [52] revealed no additional, published
RCTs using a binocular intervention for either children or
adults with unilateral amblyopia.
Methods/design
Aim and hypothesis
The primary aim of this trial is to investigate whether
6 weeks of binocular treatment leads to a greater im-
provement in amblyopic eye visual acuity than 6 weeks
of a placebo treatment. The trial will also assess whether
binocular treatment improves stereopsis and quality oflife, and reduces interocular suppression to a greater ex-
tent than placebo treatment. Furthermore, compliance
and participant acceptability of the home-based video-
game treatment will also be addressed. We hypothesise
that binocular treatment will lead to greater improve-
ments in monocular (near and distance visual acuity)
and binocular (stereopsis and suppression) visual func-
tion after 6 weeks of treatment compared to placebo
treatment.
Study design and recruitment
This is a double-blind, randomised, placebo-controlled
multicentre trial. Five trial sites are involved, namely:
School of Optometry and Vision Science, the University
of Auckland, Auckland, New Zealand; School of Optom-
etry and Vision Science, University of Waterloo, Waterloo,
Canada; The Centre for Eye Research Australia, Royal Vic-
torian Eye and Ear Hospital, Melbourne, Australia; McGill
Vision Research, Department of Ophthalmology, McGill
University, Montreal, Canada; and the School of Optom-
etry, Hong Kong Polytechnic University, Hong Kong. Data
will be collected in both clinical and psychophysical
laboratory settings depending on the facilities available
at each site.
Potential participants will be identified through referrals
by ophthalmologists and optometrists, clinical record
searches and public advertisements. Potential participants
(and parents/guardians of potential child participants) will
contact a study team member and will be provided with
an information sheet. Interested participants will complete
a telephone screening and, if appropriate, will be invited
for an eligibility and baseline assessment by the study staff.
Recruitment began on 13 March 2014 and is scheduled to
end on the 31 May 2016.
Eligibility
The following eligibility criteria exist for this trial:
 Age 7 years or older
 Amblyopia associated with the presence or history
of strabismus, anisometropia or both (mixed
mechanism)
 Unilateral amblyopia, defined as best-corrected
amblyopic eye visual acuity (VA) of 0.30–1.00
LogMAR inclusive, fellow eye VA ≤0.10 LogMAR
and an interocular VA difference ≥ 0.20 log units.
VA will be measured using the electronic Early
Treatment for Diabetic Retinopathy Study (E-ETDRS)
protocol presented on an Electronic Visual Acuity
(EVA) testing system [55]
 Strabismic amblyopia, defined as amblyopia in the
presence of heterotropia at distance and/or near
fixation, a history of strabismus surgery, or resolution
of strabismus following hyperopic spectacle correction
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the presence of a spherical equivalent difference
≥0.50 dioptres (D) between the eyes, or a difference
of astigmatism in any meridian ≥1.50 D and no
strabismus
 Mixed-mechanism amblyopia, defined as amblyopia
in the presence of both strabismus and anisometropia
 An ability to align a dichoptically presented nonius
cross within the screen area of an iPod touch device.
This criterion ensures that successful play of the
treatment game is possible
 Willing and able to provide written informed
consent for participation in the study
 Stable visual acuity with full optical correction
Exclusion criteria are: myopia of spherical equivalent
power more than −6.00 D in either eye; previous intraocu-
lar surgery; ocular pathology; a diagnosed neurological
condition (judged on a case-by-case basis by the Trial
Steering Committee).
Optical treatment
Participants will be required to wear their full optical
correction in spectacles or contact lenses prior to ran-
domisation. Optical correction will meet the criteria de-
signed by the Paediatric Eye Disease Investigator Group
and will be based on a cycloplegic refraction that is
within 6 months of study entry (a new cycloplegic refrac-
tion will be provided if necessary): (1) hypermetropia will
not be under-corrected by more than +1.50 D spherical
equivalent and the reduction in plus sphere must be iden-
tical between the two eyes, (2) spherical equivalent power
will be ≤ ±0.50 D of fully correcting the anisometropia, (3)
cylinder power in each eye will be ≤ ±0.50 D of fully
correcting the astigmatism for each eye and, (4) cylinder
axis of the correction for each eye must be ≤ ±6° of the
axis identified during cycloplegic refraction when cylinder
power is ≥1.00 D.
Participants who have worn full optical correction
full-time for more than 16 weeks and meet all eligibility
criteria will be randomised immediately after baseline
examination. Participants who have not been wearing
full optical correction full-time for 16 weeks but are
otherwise eligible will complete an optical treatment
period of up to 16 weeks before randomisation. If they
remain eligible, participants undergoing optical treat-
ment will be randomised when the visual acuity in the
amblyopic eye is stable, defined as a change of ≤0.1
LogMAR over two measurements made at least 4 weeks
apart. Participants will not be eligible if their visual
acuity does not stabilise over 16 weeks of refractive
adaptation, or if they are unable to wear optical correction
full-time, or if their amblyopic eye visual acuity improves
to the point that they no longer meet the eligibility criteria.Randomised participants will be asked to wear their op-
tical correction full-time until their final follow-up visit is
complete. This aspect of the protocol is designed to
minimise the effect of optical treatment on the outcome
measures of the trial.
Written informed consent will be obtained and eligi-
bility assessed at the baseline visit. Participants who are
eligible will be randomised and begin treatment. Partici-
pants who require optical treatment but are otherwise
eligible will be provided with optical correction and
enter the optical treatment process. Participants who re-
main eligible after optical treatment will be randomised
and the measurements made at the end of optical treat-
ment will be used as the pretreatment baseline.
Randomisation and blinding
Allocation concealment procedures will be followed. Eli-
gible participants will be allocated randomly in a 1:1
ratio by computer to either the active or placebo treat-
ment group, using minimisation stratified by three age
groups (7–12, 13–17 and 18 years and over). Participants
and study investigators will remain blinded to treatment
allocation during the study, as will all clinical examiners/
testers involved in recruitment, data collection and data
entry until final data lock. Independent study staff respon-
sible for randomisation and allocation of the game-
specific device to participants will not be blinded. Partici-
pants will be informed of the study results at the end of
the study and participants randomised to the placebo
group will be offered the treatment if the trial is positive.
There is a possibility that participants may attempt
to guess their allocated group (active or placebo) by
observing the game and, therefore, become unblinded.
A number of steps will be taken to minimise this risk.
No details regarding the principles underlying the
game design, such as contrast balancing or the presen-
tation of different game elements to each eye, will be
provided to participants. Also, study staff will be
instructed not to answer questions from participants
relating to their allocated group. In addition, study clini-
cians who assess treatment outcomes will be instructed
not to handle the training iPod to prevent accidental
unblinding.
Treatment allocation
Participants will be randomised to receive 6 weeks of ac-
tive or placebo home-based binocular treatment in the
form of an interactive falling-blocks game implemented
on a 5th generation iPod touch device viewed through
red/green anaglyphic glasses (Fig. 1). Participants will begin
their treatment within 1 day of randomisation. Participants
will be instructed to play the videogame for 1–2 h every
day (separated into a maximum of three daily sessions) for
6 weeks while wearing red/green anaglyphic glasses and
Fig. 1 Study schematic. Legend: study flow from recruitment and screening to the final 24-week follow-up
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will terminate automatically on the iPod 44 days after ran-
domisation, regardless of the scheduled follow-up clinical
visit, to ensure consistent dosing for all participants. This
trial uses a 6-week treatment period as previous studies
indicate that this duration is sufficient for significant
improvements [35, 37, 39, 40] and that compliance is
high early in therapy but begins to fall after 6 weeks if
the game is not changed.Active group In the active treatment game, a subset of
blocks is presented to the amblyopic eye at high contrast
(100 %) and other blocks are presented to the fellow
eye at low contrast tailored to each individual’s level of
interocular suppression determined by a random-dot
kinematogram measure of suppression [30, 33] and an
assessment of the participant’s ability to play the game
by an unblinded assessor. Red-green anaglyphic glasses
(in addition to spectacle correction, if any; green lens
over the amblyopic eye) are used to split the images be-
tween the two eyes. The contrast of the blocks presented to
the fellow eye will be increased if participants play the game
successfully. Specifically, if the patient achieves a score of
1000 and played for more than 15 min within a 24-h
period, the fellow eye contrast will be increased by 15 % for
the next 24-h period of play. If the game is attempted for
over 15 min but a score of 1000 is not achieved, the fellow
eye contrast will be reduced by 5 %. In all other situations
the fellow eye contrast will remain constant.Control group The placebo treatment game will be
identical to the active treatment game except that both eyes
will see the same images with no contrast offset. All partici-
pants will be required to wear red-green anaglyphic glasses
on top of their optical correction during game play.
Both the treatment and placebo games include a
dichoptically presented, contrast-balanced alignment cali-
bration at the start of each treatment session. The partici-
pants will be presented with a dichoptic nonius cross that
they are required to align using directional arrow buttons
presented on the iPod screen. In the active game, the
alignment information will be used to offset the relative
position of the blocks shown to each eye to ensure proper
alignment during game play.
The iPod devices will automatically record treatment
information including contrast change, alignment calibra-
tion, scores achieved and compliance (time spent playing
the game).Outcomes
Outcome measures will be assessed at 3, 6, 12 and
24 weeks post randomisation by blinded assessors. Base-
line and outcome measures are summarised in Table 1.Primary outcome
The primary outcome is the change in best-corrected
distance visual acuity in the amblyopic eye from baseline
to 6 weeks post randomisation, measured using the highly
standardised E-ETDRS protocol EVA testing system [55].
Table 1 Schedule of assessments
Randomisation 3 weeks 6 weeks 12 weeks 24 weeks
Demography √
Visual acuity √ √ √ √ √
Stereopsis √ √ √ √ √
Angle of strabismus (if applicable) √ √ √ √ √
Interocular suppression √ √ √ √ √
Interocular contrast √ √
Treatment compliance √ √
Treatment acceptability √ √
Quality of life (18 years and over) √ √
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 Change from baseline in best-corrected distance visual
acuity in the amblyopic eye, fellow eye and both eyes
at 3, 6, 12 and 24 weeks post randomisation
 Change from baseline in best-corrected near visual
acuity in the amblyopic eye, fellow eye and both eyes
at 3, 6, 12 and 24 weeks post randomisation measured
using the Lighthouse ETDRS near visual acuity chart
 Change from baseline in stereopsis at 3, 6, 12 and
24 weeks post randomisation measured using Randot
Preschool Stereotest [56]
 Change from baseline in angle of strabismus (where
applicable) at 3, 6, 12 and 24 weeks post randomisation
measured using the Simultaneous prism Cover Test at
near and distance [22]
 Change from baseline in interocular suppression at
3, 6, 12 and 24 weeks post randomisation measured
using Worth Four-dot Test at 33 cm and at 6 m and
a prototype iPod-based version of the Dichoptic
Motion Coherence Test [8, 10, 33]
 Change from baseline in interocular contrast at 3
and 6 weeks post randomisation based on the log
file extracted from the iPod
 Change in quality of life from baseline to 24 weeks
post randomisation measured in adult participants
only (18 years of age or older) using the World Health
Organisation Quality of Life (WHOQOL) – BREF [57]
 Treatment compliance at 3 and 6 weeks post
randomisation. Participants’ compliance will be
recorded in two ways: through data stored on the
iPod device and through a diary provided to
participants. Compliance will be defined as at least
25 % of the prescribed dose (i.e. playing the game
for at least 5 h 15 min at 3 weeks and for at least
10 h 30 min at 6 weeks post randomisation) [37]
 Treatment acceptability at 3 and 6 weeks post
randomisation, assessed using a modified version of
the Amblyopia Treatment Index questionnaire for
children and adults [58, 59]. This questionnaire has5-point Likert Scales for a series of 20 questions for
parents of participants aged 7–17 years and 19
questions for participants aged 18 years and over
 Adverse events. No cases of diplopia have been
reported in published studies of contrast balanced
binocular treatment, possibly because the treatment
is designed to promote binocular function. However,
diplopia is an important issue for any amblyopia
treatment. Two cases of diplopia related to treatment
using the I-BiT system have been reported and both
cases resolved spontaneously following cessation of
treatment [53]. Therefore, binocular treatment may
carry a risk of diplopia. The potential side effect of
diplopia will be monitored throughout the study.
Diplopia will be discussed upon randomisation into
the study and will be demonstrated using two sets
of images, one printed on opaque paper and the other
on a transparency. Participants and their caregivers
(where relevant) will be asked to immediately report
any experience of diplopia to their local study team.
Study clinicians will also ask participants about
diplopia at each follow-up visit and repeat the
diplopia demonstration. If the participant reports
diplopia at any time, the condition will be assessed
by study clinicians using a diplopia questionnaire
[60, 61] and standard clinical techniques will be
used to assess the type of diplopia. If diplopia is
confirmed, the study treatment will cease and the
patient will be offered further treatment if required.
Sample size
Thirty-six participants (18 per arm) in each of the three
age groups (7–12 years, 13–17 years and 18 years and
over) will provide 90 % power at p = 0.05 to detect a
group difference of 0.20 LogMAR [62, 63] in amblyopic
eye distance visual acuity change at 6 weeks post ran-
domisation between the two treatment arms, assuming a
standard deviation of 0.17 LogMAR [32] and a 10 %
loss-to-follow-up at 6 weeks. Each age group has been
independently powered. Overall the study will aim to
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participants (18 per arm) in each of the three age groups
(7–12 years, 13–17 years and 18 years and over).
Analyses
During the trial, data will be entered into a secure data-
base with range checks for each data field. Anonymised
paper copies of forms will be stored in secure locked fil-
ing cabinets. The final dataset will be made available to
study team members upon approval from the Steering
Committee.
The effect of the intervention will be evaluated between
the active and placebo groups for the whole cohort and
for each of three age groups; 7–12 years, 13–17 years and
18 years and over. This design will allow for a direct
comparison to the current ‘gold standard’ clinical trial
of monocular amblyopia treatment in older children
(7–12 and 13–17 age groups) [22].
Statistical analyses will be performed using SAS ver-
sion 9.4 (SAS Institute Inc. Cary, NC, USA) and will
follow a prespecified statistical analysis plan. No in-
terim analyses are planned. All statistical tests will be
two-sided at the 5 % significance level. Treatment eval-
uations for the primary outcome will be carried out on
an intention-to-treat (ITT) basis, where the ‘last value
carried forward’ method will be used to replace missing
data. Sensitivity analyses will be conducted to test the
robustness of the primary outcome results. These will
include per protocol analysis (excluding participants
who have major protocol violations such as poor compli-
ance, loss to follow-up and missing data), complete case
analysis, and ITT analyses using multiple imputation to
replace missing values in the primary outcome.
Baseline demographics, visual acuity, stereopsis, suppres-
sion, and quality of life will be summarised using descrip-
tive statistics by treatment arms. The primary outcome and
quality of life data will be analysed using linear regression.
Repeated measures mixed models will be applied to other
continuous outcomes measured repeatedly over time and
the interaction effect between treatment and visit will be
tested. For all continuous outcomes the baseline outcome
value and age groups (stratification factor) will be adjusted
for in the regression models. The model-adjusted treatment
difference will be reported, with associated 95 % confidence
interval and p value. Generalised linear regression models
will be applied to categorical outcomes as appropriate.
Results will be published and presented to the relevant
professional groups.
Monitoring
An independent monitor will check the existence and
correct date for all signed Consent Forms. The monitor
will also sample over 10 % of all randomised participants
to check data within the database against source data.The Health Research Council of New Zealand Data
Safety Monitoring Core Committee considered the trial
to be low risk and, therefore, did not recommend estab-
lishing a Data Safety Monitoring Committee for the trial.
Discussion
This is the first RCT for amblyopia in older children and
adults using a binocular treatment approach. This study
builds upon previous case-series studies to evaluate the
efficacy of a home-based binocular videogame for improv-
ing amblyopic eye visual acuity. This study also aims to
determine whether this novel treatment reduces interocu-
lar suppression and improves stereopsis.
The specific binocular videogame treatment being used
in this trial is a prototype that is based on the principle of
providing contrast-balanced dichoptic stimuli to patients
with amblyopia in order to promote binocular function. If
the treatment is effective, this general principle could
be applied to a wide variety of videogame genres and
platforms to enhance patient engagement and tailor the




D: Dioptre; E-ETDRS: Early Treatment for Diabetic Retinopathy Study;
EVA: Electronic Visual Acuity; ITT: Intention-to-treat; LogMAR: Logarithm of
the minimum angle of resolution; RCT: Randomised controlled trial;
VA: Visual acuity; WHOQOL – BREF: World Health Organisation Quality of Life
questionnaire – Brief
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